{
    "clinical_study": {
        "@rank": "80711", 
        "arm_group": [
            {
                "arm_group_label": "VAC-3S 16\u00b5g/ml", 
                "arm_group_type": "Active Comparator", 
                "description": "VAC-3S 16\u00b5g/ml administered every 4 weeks for 3 months followed by 3 maintenance vaccinations every 12 weeks after the third initial vaccination."
            }, 
            {
                "arm_group_label": "VAC-3S Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "VAC-3S placebo administered every 4 weeks for 3 months followed by 3 maintenance vaccinations every 12 weeks after the third initial vaccination."
            }, 
            {
                "arm_group_label": "VAC-3S 32 \u00b5g/ml", 
                "arm_group_type": "Active Comparator", 
                "description": "VAC-3S 32\u00b5g/ml administered every 4 weeks for 3 months followed by 3 maintenance vaccinations every 12 weeks after the third initial vaccination."
            }, 
            {
                "arm_group_label": "VAC-3S 64 \u00b5g/ml", 
                "arm_group_type": "Active Comparator", 
                "description": "VAC-3S 64\u00b5g/ml administered every 4 weeks for 3 months without maintenance vaccination."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the protective effect of VAC-3S in controlled HIV\n      patients receiving standard of care antiretroviral treatment."
        }, 
        "brief_title": "Assessment of the Therapeutic Properties of the VAC-3S Immunoprotective Vaccine When Combined With Standard ART in the Course of HIV-1 Infection", 
        "condition": "HIV", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Documented HIV-1 infection,\n\n          2. Adults > 18 and < 60 years of age,\n\n          3. Able and willing to comply with the protocol, including availability for all\n             scheduled study visits,\n\n          4. Provided a signed written informed consent,\n\n          5. Meets study screening physical, medical history and laboratory assessments (defined\n             below),\n\n          6. On stable antiretroviral therapy that is consistent with the current standard of care\n             for at least 12 months prior to study screening,\n\n          7. Plasma HIV RNA < 50 cps/mL during the previous 12 months,\n\n          8. CD4+ T cell count at screening > 200 and < 500 cells/mm3,\n\n          9. Adequate hematology, biochemistry, and metabolic blood tests defined as being less\n             than grade 2 according to the Division of AIDS Adverse Events (See Appendix 23.1),\n             except for the numeration of CD4 and for the numeration of lymphocytes,\n\n         10. Adequate hepatic and renal function defined as being less than Grade 2 according to\n             the Division of AIDS Adverse Events (See Appendix 23.1),\n\n         11. Female patients of childbearing age with one documented negative blood pregnancy\n             tests between Screening and Visit 1/Month 0; Female patient of childbearing potential\n             must be receiving two forms of effective contraception and must be willing to use\n             them throughout the study duration. These include oral, transdermal, systemic or\n             implant contraception birth control, intra-uterine devices (IUD), abstinence and\n             double barrier method such as diaphragm with spermicidal gel or other recommended\n             double barrier method,\n\n         12. Affiliated with the National Medical Insurance System,\n\n         13. Believed by investigator to be able and willing to comply with the requirements of\n             the study protocol and will be available for all scheduled visits at the study site.\n\n        Exclusion Criteria:\n\n          1. Not meeting all of the inclusion criteria listed above,\n\n          2. Administration of any investigational drug or device within 28 days prior to\n             screening,\n\n          3. Prior history of an AIDS-defining event,\n\n          4. Active co-infection with either HCV or HBV or any other active viral hepatitis\n             co-infection,\n\n          5. Any acute or clinically significant infections within the past month,\n\n          6. Known allergy or intolerance to components of VAC-3S as documented through medical\n             records or via patient interview,\n\n          7. Chronic active liver disease as documented by any of the following laboratory\n             assessments: ultrasound, clinical assessment, liver biopsy or equivalent non-invasive\n             methods,\n\n          8. Receipt of any known vaccinations within the past 1 month prior to screening,\n\n          9. Receipt of any agent in the past 12 months that exerts a known immunological effect\n             (e.g. includes but not limited to IL-2, IL-7, growth hormone\u2026),\n\n         10. Patients with Insulin Dependent Diabetes Mellitus, patients receiving anti-diabetic\n             treatment, anticoagulants (excluding daily \"baby-dose\" aspirin) or daily NSAIDs\n             within one week of study enrollment,\n\n         11. Receipt of any contraindicated medications listed in Appendix 23.2,\n\n         12. History of or active auto-immune disease,\n\n         13. Acute or chronic psychiatric conditions which in the opinion of the investigator\n             would need continual psychological support and/or medications incompatible with study\n             participation,\n\n         14. Patients with contraindications to intramuscular injections including, but not\n             limited to, patients with thrombocytopenia and/or anomalies of the coagulation\n             system,\n\n         15. Any uncontrolled chronic or acute condition that in the opinion of the investigator\n             would compromise safety of the patient or the ability to properly administer the\n             study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02041247", 
            "org_study_id": "IPROTECT1", 
            "secondary_id": "2013-002735-23"
        }, 
        "intervention": {
            "arm_group_label": [
                "VAC-3S 16\u00b5g/ml", 
                "VAC-3S Placebo", 
                "VAC-3S 32 \u00b5g/ml", 
                "VAC-3S 64 \u00b5g/ml"
            ], 
            "intervention_name": "VAC-3S", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 15, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Laurent Cotte, Dr", 
                    "phone": "+33 (0)4 72 07 18 99"
                }, 
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France", 
                        "zip": "69317"
                    }, 
                    "name": "H\u00f4pital de la Croix Rousse"
                }, 
                "investigator": {
                    "last_name": "Laurent Cotte, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jacques Reynes, Pr", 
                    "phone": "+33 (0)4 67 33 72 14"
                }, 
                "facility": {
                    "address": {
                        "city": "Montpellier", 
                        "country": "France", 
                        "zip": "34295"
                    }, 
                    "name": "H\u00f4pital Gui de Chauliac"
                }, 
                "investigator": {
                    "last_name": "Jacques Reynes, Pr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Christine Katlama, MD, PhD", 
                    "phone": "+33 1 42 16 01 42"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75013"
                    }, 
                    "name": "H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re"
                }, 
                "investigator": {
                    "last_name": "Christine Katalama, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Pierre-Marie Girard, Pr", 
                    "phone": "+33 (0)1 49 28 24 38"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75012"
                    }, 
                    "name": "H\u00f4pital Saint-Antoine"
                }, 
                "investigator": {
                    "last_name": "Pierre-Marie Girard, Pr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Odile Launay, Pr", 
                    "phone": "+33 (0)1 58 41 28 58"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75014"
                    }, 
                    "name": "H\u00f4pital Cochin Saint Vincent de Paul"
                }, 
                "investigator": {
                    "last_name": "Odile Launay, Pr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Gilles Pialoux, Pr", 
                    "phone": "+33 (0)1 56 01 74 12"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75020"
                    }, 
                    "name": "H\u00f4pital Tenon"
                }, 
                "investigator": {
                    "last_name": "GIlles Pialoux, Pr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Anne Simon, Dr", 
                    "phone": "+33 (0)1 42 16 10 93"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75013"
                    }, 
                    "name": "H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re"
                }, 
                "investigator": {
                    "last_name": "Anne Simon, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "J\u00fcrgen Rockstroh, Pr", 
                    "phone": "+49 (0)228 287 16558"
                }, 
                "facility": {
                    "address": {
                        "city": "Bonn", 
                        "country": "Germany", 
                        "zip": "53105"
                    }, 
                    "name": "J\u00fcrgen Rockstroh"
                }, 
                "investigator": {
                    "last_name": "J\u00fcrgen Rockstroh, Pr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jose Gatell, Pr", 
                    "phone": "+34 (0)93 227 54 30"
                }, 
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08036"
                    }, 
                    "name": "Hospital Clinic University of Barcelona"
                }, 
                "investigator": {
                    "last_name": "Jose Gatell, Pr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "France", 
                "Germany", 
                "Spain"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "Assessment of the Therapeutic Properties of the VAC-3S Immunoprotective Vaccine When Combined With Standard Antiretroviral Therapy (ART) in the Course of HIV-1 Infection. A European, Randomized, Double Blind Placebo-controlled Phase II Study", 
        "overall_contact": {
            "last_name": "Rapha\u00ebl Ho Tsong Fang, DVM, PhD", 
            "phone": "+33 1 60 87 89 40"
        }, 
        "overall_official": {
            "affiliation": "InnaVirVax", 
            "last_name": "raphael ho tsong fang, DVM PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
                "Germany: Paul-Ehrlich-Institut", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "anti-3S antibodies titer", 
            "safety_issue": "No", 
            "time_frame": "From D0 to week 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02041247"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "safety parameter changes according to the DAIDS (Division of Acquired Immunodeficiency Syndrome) adverse events (AEs) grading table.Safety parameters include adverse events, vital signs, physical examinations, laboratory tests (hematology, blood chemistry, viral load, CD4 and CD8 counts)", 
                "measure": "tolerance to 6 vaccinations of VAC-3S", 
                "safety_issue": "No", 
                "time_frame": "From D0 to week 72"
            }, 
            {
                "description": "Inflammatory markers include: Highly sensitive C-reactive protein (hsCRP), Highly sensitive Recombinant human interleukin 6 (hsIL-6), Soluble CD14 (sCD14), Soluble CD163 (sCD163), D-dimer, Interferon (IFN)-gamma inducible protein 10 (IP-10), Tumor necrosis factor receptor 1 (sTNFR1) and 2 (sTNFR2), Immunoglobulin G (IgG),", 
                "measure": "blood inflammatory marker concentrations", 
                "safety_issue": "No", 
                "time_frame": "From D0 to week 72"
            }, 
            {
                "description": "anti-3S antibody titers and determination of anti-3S antibody isotypes and avidity", 
                "measure": "immunogenic characteristics of VAC-3S", 
                "safety_issue": "No", 
                "time_frame": "From D0 to week 72"
            }, 
            {
                "description": "Phenotype markers include: Nkp44L expression on the surface of CD4+ T lymphocytes, phenotypic markers of of lymphocyte differentiation and activation", 
                "measure": "lymphocyte phenotype markers", 
                "safety_issue": "No", 
                "time_frame": "From D0 to week 72"
            }, 
            {
                "description": "3S gp41 sequences and  proviral HIV reservoir", 
                "measure": "secondary virological effects", 
                "safety_issue": "No", 
                "time_frame": "From D0 to week 72"
            }
        ], 
        "source": "InnaVirVax", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "InnaVirVax", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}